Serum levels of Ang2 were elevated at baseline in 143 breast cancer patients compared to 100 healthy controls, and the 5-year overall survival was significantly lower in the Ang2 high expression group compared to patients with low serum Ang2 [39]. This evidence concerns the gene ANGPT2 and breast carcinoma.